---

---

therapeutics   publishing date : 2023 - 01 - 31   

save search

---

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-01-31 (Crawled : 14:20) - globenewswire.com
SPRO | $1.465 4.27% 91K |

Health Technology

| -23.78% | O: 0.0% H: 3.78% C: 1.62%
nasdaq grants therapeutics

---

AN2 Therapeutics to Present at SVB Securities Global Biopharma Conference
Published: 2023-01-31 (Crawled : 00:00) - biospace.com/
ANTX | $2.39 1.27% 60K |

| -80.81% | O: -0.57% H: 0.16% C: -0.57%
biopharma global conference therapeutics

---

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-01-31 (Crawled : 00:00) - globenewswire.com
SRPT | $117.93 0.83% 250K |

Health Technology

| -6.41% | O: 0.02% H: 0.38% C: -2.11%
nasdaq grants therapeutics

---

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma Study provides additional support for further advancement of TTX-RIGA
Published: 2023-01-31 (Crawled : 23:00) - biospace.com/
RNAZ | $0.461 0.44% 70K |

Professional, Scientific, and T...

| -97.47% | O: -4.4% H: 8.31% C: -13.7%
melanoma preclinical immunotherapy therapeutics positive study

---

Securities Class Action Filing Activity Fell for Third Straight Year as … – Cornerstone Research
Published: 2023-01-31 (Crawled : 23:00) - spacfeed.com
EXPR | $0.83 -9.64% 440K |

Retail Trade

| -28.45% | O: -0.86% H: 4.35% C: 2.61%
TENX | $3.59 0.84% 11K |

Health Technology

| 67.92% | O: -5.66% H: 0.0% C: -15.5%
research year

---

TransCode Therapeutics Reports Positive Preclinical Results with its Immunotherapy Candidate, TTX-RIGA, in Melanoma
Published: 2023-01-31 (Crawled : 22:00) - globenewswire.com
RNAZ | $0.461 0.44% 70K |

Professional, Scientific, and T...

| -96.94% | O: 37.19% H: 3.88% C: -15.44%
melanoma preclinical immunotherapy therapeutics positive results

---

Avenue Therapeutics Announces Closing of $3.25 Million Registered Direct and Private Placement
Published: 2023-01-31 (Crawled : 19:00) - globenewswire.com
FBIO | $1.79 2.29% 89K |

Health Technology

| 92.31% | O: 0.0% H: 1.84% C: -0.93%
ATXI | $0.1301 220K |

Health Technology

| -90.58% | O: -0.72% H: 0.31% C: -2.19%
therapeutics direct

---

BioSpace Layoff Tracker 2023: INOVIO, Quince Therapeutics, Amgen and More Cut...
Published: 2023-01-31 (Crawled : 17:00) - biospace.com/
TXMD | News | $1.875 -0.27% 15K |

Health Technology

| -63.98% | O: 0.96% H: 0.0% C: -1.14%
GOOGL | News S | $158.36 1.33% 13M |

Technology Services

| 61.21% | O: -0.07% H: 2.07% C: 2.03%
GOOG | News S | $159.94 1.26% 9.4M |

Technology Services

| 61.26% | O: -0.09% H: 2.09% C: 2.05%

---

EDAP Announces Positive Results from Phase 2 Study Evaluating Therapeutic High-Intensity Focused Ultrasound (HIFU) for the Treatment of Rectal Endometriosis
Published: 2023-01-31 (Crawled : 15:00) - biospace.com/
EDAP | $7.14 -0.14% 15K |

Health Technology

| -33.8% | O: 0.93% H: 3.45% C: 0.92%
treatment positive study

---

X-Chem and Kymera Expand Existing Partnership
Published: 2023-01-31 (Crawled : 15:00) - biospace.com/
KYMR | $36.37 5.88% 240K |

Health Technology

| -5.53% | O: 0.85% H: 3.87% C: 1.94%
partnership

---

BioSpace Layoff Tracker 2023: Quince Therapeutics, Amgen, Finch and More Cut ...
Published: 2023-01-31 (Crawled : 15:00) - biospace.com/
TXMD | News | $1.875 -0.27% 15K |

Health Technology

| -63.98% | O: 0.96% H: 0.0% C: -1.14%
GOOGL | News S | $158.36 1.33% 13M |

Technology Services

| 61.21% | O: -0.07% H: 2.07% C: 2.03%
GOOG | News S | $159.94 1.26% 9.4M |

Technology Services

| 61.26% | O: -0.09% H: 2.09% C: 2.05%

---

Endonovo Retains Ocean Tomo, a Part of J.S. Held, to Provide Fairness Opinion Analysis for Medical Device Spin-Off
Published: 2023-01-31 (Crawled : 14:20) - globenewswire.com
ENDV | $0.0028 158.07% 74K |

Professional, Scientific, and T...

| -80.0% | O: 24.38% H: 0.0% C: -5.53%
device medical

---

Arcturus Therapeutics Announces Clinical Trial Application for ARCT-032 Received Approval to Proceed into First-in-Human Studies to Treat Cystic Fibrosis
Published: 2023-01-31 (Crawled : 14:00) - biospace.com/
ARCT 4 | $28.69 6.02% 140K |

Health Technology

| 33.5% | O: 0.1% H: 4.14% C: 4.14%
arct-032 fibrosis application trial approval therapeutics cystic fibrosis

---

Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
CNTX | $1.48 8.82% 23K |

Health Technology

| 99.12% | O: 78.62% H: 27.05% C: -13.11%
fda breast approval cancer group elascestrant orserdu ona-xr her2- her2

---

Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
KRTX | $329.83 0.0% 1.9M |

Health Technology

| 69.14% | O: 0.74% H: 3.19% C: 1.5%
commercial therapeutics

---

Casma Therapeutics Announces CEO Transition
Published: 2023-01-31 (Crawled : 13:20) - biospace.com/
CRIS | $14.73 -0.81% 3.4K |

Health Technology

| 1835.86% | O: 0.64% H: 2.2% C: -5.04%
ceo therapeutics

---

Medicenna to Present at the 2023 Guggenheim Oncology Conference
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
MDNA | $0.157 -0.32% 1.3M |

Health Technology

| -77.79% | O: 3.92% H: 3.32% C: -0.44%
conference

---

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27Axsome to host conference call and webcast on Monday, Feb. 27, 2023, at 8:00 a.m. ET
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
AXSM | $73.45 3.31% 420K |

Health Technology

| -3.01% | O: 0.0% H: 3.64% C: 2.31%
conference report year therapeutics financial results

---

Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program
Published: 2023-01-31 (Crawled : 13:00) - prnewswire.com
COEP | $0.355 49K |

| -78.79% | O: 13.33% H: 4.28% C: -0.53%
research program therapeutics agreement

---

PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE
Published: 2023-01-31 (Crawled : 13:00) - biospace.com/
GLAXF | News | $20.305 630 |

Health Technology

| 15.21% | O: 2.04% H: 0.0% C: -3.67%
PFE | News A | $26.29 0.11% 14M |

Health Technology

| -39.7% | O: -1.26% H: 2.97% C: 2.7%
GSK | News | $41.165 1.42% 1.3M |

Health Technology

| 15.58% | O: 0.85% H: 0.31% C: -0.45%
BHVN | News 0 d | $40.63 6.0% 1.4M |

Health Technology

| 106.3% | O: -0.48% H: 4.49% C: 3.24%
BNTX | News | $88.54 0.6% 220K |

Health Technology

| -37.35% | O: -1.74% H: 4.84% C: 3.88%
BEAM | $24.13 0.12% 730K |

Health Technology

| -42.76% | O: 0.21% H: 4.84% C: 2.99%
financial results

---

Gainers vs Losers

86%

14%

Top 10 Gainers

MTTR | News M | $4.56 162.07% 21M |

AGBA | $2.74 119.2% 52M |

Finance

CZOO | $9.07 81.76% 22M |

EDBL | News | $6.56 74.47% 1.8M |

MTC | $2.21 41.67% 5.6M |

Technology Services

OPRT | News | $3.12 38.67% 11M |

Finance

PALI | $6.59 33.67% 23M |

Manufacturing

VNRX | $0.7945 32.42% 3.1M |

Health Technology

MLEC | $1.81 29.29% 2.8M |

n/a

BTCM | $3.45 27.78% 640K |

Arts, Entertainment, and Recrea...

---

Your saved searches

---